The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

(Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01. ・Relmada also announced that it has entered into a securities ...

Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...

An aggressive bladder cancer diagnosis made 2025 one of the toughest years of Deion Sanders’ life. Coach Prime underwent a ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...